Loading...
By Amy Orciari Herman
The FDA is planning an in-depth study of generic extended-release metoprolol succinate after receiving nearly 3500 complaints related to the blood pressure drug since 2009, Bloomberg News reports. Complaints include both lack of effectiveness and side effects.
The investigation began in response to concerns from a Cleveland Clinic cardiologist who, in 2012, said the metoprolol pills he was prescribing were not working consistently.
The analysis will examine whether generic versions of the drug are "chemically the same as the original" (brand name, Toprol XL). The news article notes that generic makers don't copy extended-release technology the way they do the actual drug. In 2008, over 6 million bottles of generic metoprolol were recalled because they potentially failed to meet certain specifications.
Harlan Krumholz, editor-in-chief of NEJM Journal Watch Cardiology, commented: "The availability of generic drugs can save the health system billions, but we must be sure they have the same risk/benefit profile. This study may herald an era where we begin to ask more questions about the safety and effectiveness of these generics."
The FDA's study may begin by September and could last up to 3 years.
Comment
LINK(S):
Bloomberg News story (Free)